Sanofi US and Actress Elizabeth Perkins Premiere Documentary -- Diabetes
Co-Stars Presents "Strength in Numbers"
-Donation to Diabetes Hands Foundation Doubled When Documentary Reaches 10,000
BRIDGEWATER, N.J., May 6, 2013
BRIDGEWATER, N.J., May 6, 2013 /PRNewswire/ --Sanofi US and Golden Globe and
Emmy nominated actress Elizabeth Perkins proudly premiered the Diabetes
Co-Stars documentary, "Strength in Numbers," at the American Diabetes
Association Expo in Los Angeles, CA this past weekend. The film, produced by
Elizabeth and her 'co-star' and husband Julio Macat, features her diabetes
story as well as two other inspirational stories from the 2012 Diabetes
Co-Stars casting call contest – best friends Amanda Bauer and Anne Casey from
New York, and father-daughter duo Eugenio and Naiomi Rivera from Texas.
To view the multimedia assets associated with this release, please click
The pairs were selected because of their empowering stories of dedication and
support, with Amanda and Anne giving back to their community by spearheading
support groups for youth living with diabetes, and Eugenio and Naiomi guiding
one another through their daily diabetes management. The documentary
highlights their stories, in addition to Elizabeth and Julio's, and can be
viewed online at www.DiabetesCoStars.com.
"Hearing these stories, I truly identified with the level of support and
caring these people showed one another and was so excited to feature them in
this documentary," said Elizabeth Perkins, star of the new ABC sitcom 'How to
Live with Your Parents (For the Rest of Your Life).' "The Diabetes Co-Stars
program is close to my heart because it celebrates those who support the 26
million Americans living with diabetes every day and this film shines a light
on these inspiring people."
Perkins, who is living with type 1 diabetes, produced the documentary as part
of her partnership with Sanofi US on the Diabetes Co-Stars campaign, which has
brought awareness to millions of Americans about the power of a support team
for people living with diabetes since the program's launch in 2010. She
currently uses Lantus^® SoloSTAR^® (insulin glargine [rDNA origin] injection)
as part of her overall diabetes treatment plan, along with exercise, healthy
diet and the support from her family and friends.
As part of the program, Sanofi US is supporting the Diabetes Hands Foundation
and its efforts to encourage an open dialogue around the realities of living
"We are so thankful to Sanofi US for their continued support in our mission to
connect, engage, and empower people touched by diabetes," said Manny Hernandez
Co-Founder and President of Diabetes Hands Foundation. "You can make an even
bigger impact by watching the documentary online."
When "Strength in Numbers" reaches 10,000 online views, Sanofi US will double
its initial donation for a total of $20,000.
To learn more about how you can support your loved ones with diabetes, please
visit www.DiabetesCoStars.com, and follow the Sanofi US Diabetes Facebook page
and Twitter feed for additional updates.
Indications and Usage for Lantus (insulin glargine [rDNA origin] injection)
Prescription Lantus is a long-acting insulin used to treat adults with type 2
diabetes and adults and children (6 years and older) with type 1 diabetes for
the control of high blood sugar. It should be taken once a day at the same
time each day to lower blood glucose.
Do not use Lantus to treat diabetic ketoacidosis.
Important Safety Information for Lantus (insulin glargine [rDNA origin]
Do not take Lantus if you are allergic to insulin or any of the inactive
ingredients in Lantus.
You must test your blood sugar levels while using insulin, such as Lantus. Do
not make any changes to your dose or type of insulin without talking to your
healthcare provider. Any change of insulin should be made cautiously and only
under medical supervision.
Do NOT dilute or mix Lantus with any other insulin or solution. It will not
work as intended and you may lose blood sugar control, which could be
serious. Lantus must only be used if the solution is clear and colorless with
no particles visible. Do not share needles, insulin pens or syringes with
The most common side effect of insulin, including Lantus, is low blood sugar
(hypoglycemia), which may be serious. Some people may experience symptoms such
as shaking, sweating, fast heartbeat, and blurred vision.Severe hypoglycemia
may be serious and life threatening.It may cause harm to your heart or
brain.Other possible side effects may include injection site reactions,
including changes in fat tissue at the injection site, and allergic reactions,
including itching and rash.In rare cases, some allergic reactions may be life
Tell your doctor about other medicines and supplements you are taking because
they can change the way insulin works.Before starting Lantus, tell your
doctor about all your medical conditions including if you have liver or kidney
problems, are pregnant or planning to become pregnant, or are breast-feeding
or planning to breast-feed.
Lantus SoloSTAR is a disposable prefilled insulin pen. Please talk to your
healthcare provider about proper injection technique and follow instructions
in the Instruction Leaflet that accompanies the pen.
For Full Prescribing Information for Lantus^® please visit www.Lantus.com or
Diabetes is a chronic, widespread condition in which the body does not produce
or properly use insulin, the hormone needed to transport glucose (sugar) from
the blood into the cells of the body for energy. It is estimated that 371
million people worldwide and nearly 26 million Americans have diabetes,
including an estimated 7 million Americans who remain undiagnosed. At the same
time, approximately 40 percent of those diagnosed are not achieving the blood
sugar control target of A1C <7 percent recommended by the American Diabetes
Association (ADA). The A1C test measures average blood glucose levels over the
past two-to three-month period.
About Sanofi Diabetes
Sanofi strives to help people manage the complex challenge of diabetes by
delivering innovative, integrated and personalized solutions. Driven by
valuable insights that come from listening to and engaging with people living
with diabetes, the Company is forming partnerships to offer diagnostics,
therapies, services, and devices including innovative blood glucose monitoring
systems. Sanofi markets both injectable and oral medications for people with
type 1 or type 2 diabetes. Investigational compounds in the pipeline include
an injectable GLP-1 agonist being studied as a single agent, in combination
with basal insulin, and/or in combination with oral antidiabetic agents.
Sanofi, a global and diversified healthcare leader, discovers, develops and
distributes therapeutic solutions focused on patients' needs. Sanofi has core
strengths in the field of healthcare with seven growth platforms: diabetes
solutions, human vaccines, innovative drugs, rare diseases, consumer
healthcare, emerging markets and animal health. Sanofi is listed in Paris
(EURONEXT: SAN) and in New York (NYSE: SNY).
Sanofi is the holding company of a consolidated group of subsidiaries and
operates in the United States as Sanofi US. For more information on Sanofi US,
please visit http://www.sanofi.us or call 1-800-981-2491.
Specialist, U.S. Communications
Tel.: (908) 981-6673
SOURCE Sanofi US
Press spacebar to pause and continue. Press esc to stop.